Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,266 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $19,646.22. Following the completion of the sale, the general counsel now owns 33,510 shares of the company’s stock, valued at approximately $290,531.70. This trade represents a 6.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Stoke Therapeutics Stock Performance

STOK stock opened at $8.33 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $5.80 and a 1 year high of $17.58. The stock has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99. The stock’s fifty day moving average is $9.49 and its two-hundred day moving average is $11.49.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. As a group, analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STOK. Toronto Dominion Bank bought a new stake in Stoke Therapeutics during the 4th quarter valued at $35,001,000. RTW Investments LP raised its stake in shares of Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after purchasing an additional 471,240 shares in the last quarter. Norges Bank acquired a new stake in Stoke Therapeutics in the fourth quarter worth about $3,472,000. Tang Capital Management LLC bought a new position in Stoke Therapeutics in the 4th quarter valued at about $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Stoke Therapeutics during the 4th quarter valued at about $3,218,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.